Comparative Pharmacology
Head-to-head clinical analysis: LINEZOLID versus ZYVOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINEZOLID versus ZYVOX.
LINEZOLID vs ZYVOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Linezolid is a synthetic antibacterial agent that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit, preventing the formation of a functional 70S initiation complex. It is a bacteriostatic agent against most susceptible organisms.
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and preventing the formation of the 70S initiation complex. It is a bacteriostatic agent against most susceptible organisms.
600 mg IV or orally every 12 hours
600 mg IV or orally every 12 hours for 10-14 days; for uncomplicated skin infections, 400 mg orally every 12 hours.
None Documented
None Documented
Clinical Note
moderateLinezolid + Haloperidol
"The risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol."
Clinical Note
moderateLinezolid + Ziprasidone
"The risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone."
Clinical Note
moderateLinezolid + Clozapine
"The risk or severity of adverse effects can be increased when Linezolid is combined with Clozapine."
Clinical Note
moderateLinezolid + Aripiprazole
Terminal elimination half-life is approximately 4.5-5.5 hours in adults with normal renal function. Half-life is not significantly altered in hepatic impairment but may be prolonged in severe renal impairment (up to 7-8 hours).
Terminal elimination half-life is approximately 4-5 hours in healthy adults, with no significant accumulation after multiple doses given twice daily.
Approximately 80% of linezolid is excreted renally as unchanged drug, with 30% as parent drug and the remainder as metabolites. About 7% is excreted in feces (biliary/fecal route).
Approximately 30% of a dose appears unchanged in urine within 24 hours, with 50% as oxidative metabolites; 10% is excreted fecally. Renal clearance accounts for ~40% of total clearance.
Category C
Category C
Oxazolidinone Antibiotic
Oxazolidinone Antibiotic
"The risk or severity of adverse effects can be increased when Linezolid is combined with Aripiprazole."